Antibody therapeutics for Ebola virus disease

Larry Zeitlin; Kevin J Whaley; Gene G Olinger; Michael Jacobs; Robin Gopal; Xiangguo Qiu; Gary P Kobinger

doi:10.1016/j.coviro.2016.01.006

Antibody therapeutics for Ebola virus disease

Curr Opin Virol. 2016 Apr:17:45-49. doi: 10.1016/j.coviro.2016.01.006. Epub 2016 Jan 27.

Authors

Larry Zeitlin¹, Kevin J Whaley², Gene G Olinger³, Michael Jacobs⁴, Robin Gopal⁵, Xiangguo Qiu⁶, Gary P Kobinger⁷

Affiliations

¹ Mapp Biopharmaceutical, Inc., 6160 Lusk Blvd #C105, San Diego, CA 92121, USA. Electronic address: larry.zeitlin@mappbio.com.
² Mapp Biopharmaceutical, Inc., 6160 Lusk Blvd #C105, San Diego, CA 92121, USA.
³ Integrated Research Facility, 8200 Research Plaza Frederick, MD 21702, USA.
⁴ Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, United Kingdom.
⁵ High Containment Microbiology Department, National Infections Service, Public Health England, 61 Colindale Avenue, London NW9 5HT, United Kingdom.
⁶ Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada; Department of Medical Microbiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.
⁷ Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada; Department of Medical Microbiology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada; Department of Immunology, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.

Abstract

With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Disease Outbreaks
Ebolavirus / immunology*
Hemorrhagic Fever, Ebola / epidemiology
Hemorrhagic Fever, Ebola / immunology
Hemorrhagic Fever, Ebola / therapy*
Humans
Immunization, Passive* / methods
Macaca / immunology
Macaca / virology
Primates / immunology
Primates / virology
Viral Load

Substances

Antibodies, Monoclonal

Grants and funding

U19 AI109762/AI/NIAID NIH HHS/United States